Advertisement
MTD vs NTRA
Which Stock Would AI Choose? Mettler-Toledo International Inc. (MTD) vs. Natera, Inc. (NTRA) Stock Comparison
Key Takeaways
- MTD reported stronger-than-expected Q2 2026 results with revenue of $1.03 billion and raised full-year guidance, reflecting demand for precision instruments in laboratory and pharmaceutical applications.
- NTRA received IVDR certification for its Signatera test across multiple cancers in July 2026 and continues to advance clinical data supporting its oncology diagnostics platform ahead of its Q2 earnings release on August 6, 2026.
- Both companies operate in healthcare-related sectors but serve distinct markets: MTD in precision measurement and weighing solutions, NTRA in genetic testing and molecular diagnostics.
- Recent market activity shows MTD benefiting from earnings momentum and margin expansion, while NTRA experiences sentiment tied to product regulatory milestones and upcoming financial results.
- Risk profiles differ, with MTD tied to industrial and lab equipment cycles and NTRA exposed to reimbursement dynamics and clinical adoption rates in genomics.
- Relative positioning favors stability for MTD following its guidance increase, whereas NTRA offers growth optionality pending earnings clarity.
Introduction
Investors and traders frequently compare MTD and NTRA to assess opportunities across precision instrumentation and molecular diagnostics within the broader healthcare sector. Mettler-Toledo International Inc. provides analytical instruments and services used in research, manufacturing, and quality control, while Natera, Inc. specializes in non-invasive genetic testing for reproductive health and oncology. This comparison appeals to market participants seeking to evaluate relative performance between established industrial healthcare suppliers and innovative diagnostics developers. The analysis focuses on observable factors such as earnings trends, product developments, and sector-specific drivers to inform portfolio positioning decisions in the current environment.
MTD Overview and Recent Performance
Mettler-Toledo International Inc. develops and manufactures precision instruments for laboratory, industrial, and food retail applications. In recent market activity, the company delivered solid second-quarter 2026 results, posting revenue of $1.03 billion that met expectations and adjusted earnings per share of $11.46, which exceeded consensus estimates. Management raised its full-year adjusted earnings guidance, citing robust demand for laboratory instruments in drug development and emerging markets alongside margin improvements and higher free cash flow. These factors contributed to positive sentiment in recent weeks, as the results highlighted operational resilience amid varying global demand patterns.
NTRA Overview and Recent Performance
Natera, Inc. focuses on cell-free DNA testing for applications in reproductive health, oncology, and organ transplantation. Recent developments include the July 2026 receipt of IVDR certification for the Signatera test across multiple cancer types, expanding its regulatory footprint in Europe. Additional clinical data presented during the period underscored the test’s utility in guiding chemotherapy decisions after colorectal cancer surgery. With second-quarter 2026 earnings scheduled for release on August 6, 2026, market attention has centered on adoption trends and reimbursement progress. Sentiment in recent weeks has reflected anticipation around these milestones alongside ongoing evaluation of the company’s growth trajectory in precision medicine.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI-powered trading bots designed for various market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, each with distinct trading styles, strategies, timeframes, performances, statistics, and sets of tickers. Only the best and most suitable bots for prevailing conditions earn placement in the Trending AI Robots section. Performance metrics across available bots typically span a wide range, with many demonstrating annualized returns between 10% and 50% or higher depending on strategy and market regime, alongside varying win rates and drawdown profiles. All the AI trading bots have different trading styles, strategies, timeframes, performances, statistics, and sets of tickers they trade. Explore the full collection at Trending AI Robots to identify options aligned with individual objectives.
Head-to-Head Comparison
MTD and NTRA operate in adjacent yet distinct segments of the healthcare ecosystem. Mettler-Toledo’s business model centers on recurring revenue from instruments, consumables, and service contracts, providing relative stability across economic cycles. Natera’s model relies on test volume growth, payer coverage, and clinical evidence generation, introducing higher variability tied to adoption and reimbursement outcomes. Recent momentum favors MTD following its earnings beat and raised guidance, while NTRA draws attention from regulatory and data catalysts ahead of its earnings report. Sector exposure places MTD in precision measurement with exposure to pharmaceutical research spending, whereas NTRA participates in the expanding genomics and personalized medicine space. Risk factors include cyclical capital spending for MTD and execution or competitive pressures for NTRA. Market sentiment reflects these contrasts, with MTD positioned on demonstrated results and NTRA on forward-looking product milestones.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, guidance revisions, and trend stability, Tickeron’s AI would currently assign a higher probability of favorable positioning to MTD relative to NTRA. The company’s demonstrated ability to exceed expectations and raise forecasts provides a clearer near-term signal compared with the pre-earnings environment surrounding NTRA. This assessment remains probabilistic and subject to evolving data, including upcoming results and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTD is a StrongBuy and NTRA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MTD’s FA Score shows that 2 FA rating(s) are green whileNTRA’s FA Score has 1 green FA rating(s).
- MTD’s FA Score: 2 green, 3 red.
- NTRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MTD’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
- MTD’s TA Score: 4 bullish, 4 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
MTD (@Medical Specialties) experienced а +1.20% price change this week, while NTRA (@Medical Specialties) price change was +15.07% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.62%. For the same industry, the average monthly price growth was +7.93%, and the average quarterly price growth was +24.12%.
Reported Earning Dates
MTD is expected to report earnings on Nov 05, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Medical Specialties (+0.62% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| MTD | NTRA | MTD / NTRA | |
| Capitalization | 28.7B | 44.8B | 64% |
| EBITDA | 1.3B | -227.7M | -570% |
| Gain YTD | 3.180 | 37.920 | 8% |
| P/E Ratio | 32.25 | N/A | - |
| Revenue | 4.13B | 2.5B | 165% |
| Total Cash | 51.4M | 1.09B | 5% |
| Total Debt | 2.11B | 240M | 880% |
MTD | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 99 | 22 | |
SMR RATING 1..100 | 2 | 96 | |
PRICE GROWTH RATING 1..100 | 15 | 36 | |
P/E GROWTH RATING 1..100 | 51 | 100 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (49) in the Biotechnology industry is somewhat better than the same rating for MTD (99) in the Medical Specialties industry. This means that NTRA’s stock grew somewhat faster than MTD’s over the last 12 months.
NTRA's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for MTD (99) in the Medical Specialties industry. This means that NTRA’s stock grew significantly faster than MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is significantly better than the same rating for NTRA (96) in the Biotechnology industry. This means that MTD’s stock grew significantly faster than NTRA’s over the last 12 months.
MTD's Price Growth Rating (15) in the Medical Specialties industry is in the same range as NTRA (36) in the Biotechnology industry. This means that MTD’s stock grew similarly to NTRA’s over the last 12 months.
MTD's P/E Growth Rating (51) in the Medical Specialties industry is somewhat better than the same rating for NTRA (100) in the Biotechnology industry. This means that MTD’s stock grew somewhat faster than NTRA’s over the last 12 months.
| MTD | NTRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 65% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 61% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 59% | 2 days ago 81% |
| Advances ODDS (%) | 2 days ago 60% | 10 days ago 80% |
| Declines ODDS (%) | 9 days ago 65% | 3 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 57% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 63% | 2 days ago 80% |
Advertisement
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | +0.09% | ||
| A - MTD | 69% Closely correlated | -0.84% | ||
| BRKR - MTD | 67% Closely correlated | +3.95% | ||
| TMO - MTD | 66% Loosely correlated | -0.33% | ||
| AZTA - MTD | 61% Loosely correlated | +0.42% | ||
| RVTY - MTD | 59% Loosely correlated | +1.86% | ||
More | ||||
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | +1.04% | ||
| ISRG - NTRA | 53% Loosely correlated | +0.01% | ||
| GH - NTRA | 50% Loosely correlated | +0.01% | ||
| ADPT - NTRA | 50% Loosely correlated | -0.55% | ||
| MTD - NTRA | 47% Loosely correlated | +0.09% | ||
| GKOS - NTRA | 47% Loosely correlated | +2.54% | ||
More | ||||